Leveraging advances in mRNA and nanotechnology, investigators demonstrate that tumor suppressor PTEN can be restored in preclinical models of prostate cancer.
Researchers examined the costs associated with screening for prostate cancer, including treatment, for three years after diagnosis. They estimated that for men diagnosed in each of 2004, 2005, 2006, and 2007, the total cost for treating and screening for each group would be $1.2 billion for three years after diagnosis.
The American Association for Cancer Research (AACR) releases its annual Cancer Progress Report highlighting how federally funded research discoveries are fueling the development of new and even more effective ways to prevent, detect, diagnose, and treat cancer.
A research team at the University of Turku in Finland discovered a link between the interplay of certain simultaneously occurring genetic changes in the HOXB13 and CIP2A genes, aggressiveness of prostate cancer, high risk of developing the disease, and poorer survival rates of patients. Prostate cancer is a major challenge in health care with over one million new cases and 300,000 deaths from it each year worldwide.
Researchers from the Keck School of Medicine of USC are looking to technology to help deconstruct expert surgeons' robotic surgery skills so they can create an objective, standardized way to train the next generation of surgeons.
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has become a popular method for determining the stage of a patient's prostate cancer. However, researchers have identified a major pitfall in this imaging technique and are cautioning medical professionals to be aware of the potential for misdiagnosis.
Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur.
Researchers have discovered a link between certain changes in the genome of a tumor and increased chances of death across multiple types of cancer.
A University of Virginia School of Medicine researcher is developing a two-fisted, antibody-based approach to destroy deadly ovarian cancer -- an approach he believes could also be modified to kill breast, prostate and other solid tumors.
Scientists have discovered a link between certain genetic mutations, the aggressiveness of prostate cancer, risk of developing the disease and poorer survival rates of patients. The gene, called ANO7, could play a vital role in improving diagnosis of prostate cancer patients. There are over 50,000 new cases and 11,000 deaths from prostate cancer each year in the UK.